Diligence memo · auto-generated · as of July 2, 2026

ProVet Investment Holdings, LLC

ProVet Investment Holdings, LLC looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

ProVet Investment Holdings, LLC operates in Pharmaceuticals, based in CHICAGO.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

ProVet Investment Holdings, LLC has raised $5.5M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $5.2M on 2016-06-06.

Most recent recorded round closed around 2018-07-17.

Valuation (modeled)modeled

Provath models ProVet Investment Holdings, LLC at approximately $11M (range $413K–$61M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.06× the median modeled value of Series A Pharmaceuticals companies in 2016–2018 (88 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 25 months.

Last raise 8.0 yr ago; this sector typically re-raises about every 13 months.

Silent for over 3× the sector's normal cadence.

The last round was 14.3× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 43% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 19% of those peers.

Closest niche peers: Arbutus Biopharma Corp, Rvc 360, Llc, Sterrx, Llc, Ribometrix, Inc., Neuraltus Pharmaceuticals, Inc..

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.